Wednesday, October 10, 2018 11:14:05 AM
Remember that when someone tries to convince you to buy or sell there is something in it for them. It's not because they are concerned about your investment.
Recent MBRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
- Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
- Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:13:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:55:19 PM
- Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data • PR Newswire (US) • 05/07/2024 12:55:00 PM
- Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 • PR Newswire (US) • 05/02/2024 01:00:00 PM
- Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin • PR Newswire (US) • 05/01/2024 12:50:00 PM
- European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference • PR Newswire (US) • 03/28/2024 02:45:00 PM
- Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity • PR Newswire (US) • 03/27/2024 01:25:00 PM
- Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML • PR Newswire (US) • 03/27/2024 01:05:00 PM
- Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial • PR Newswire (US) • 03/25/2024 11:30:00 AM
- Moleculin Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/22/2024 08:05:00 PM
- Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 03/20/2024 11:30:00 AM
- JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News • IH Market News • 03/20/2024 11:15:48 AM
- Moleculin Announces Reverse Stock Split • PR Newswire (US) • 03/19/2024 08:30:00 PM
- Moleculin to Present at the 36th Annual ROTH Conference • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 02:30:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/16/2024 10:19:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:15:29 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM